注射用纤溶酶药物利用评价标准的建立与应用

Establishment and application of drug use evaluation criteria of fibrinogenase for injection

目的 建立注射用纤溶酶药物利用评价(DUE)标准,为临床合理应用注射用纤溶酶提供参考。方法 以注射用纤溶酶药品说明书为基础,参考相关指南与文献,并通过专家咨询法,从用药指征、用药过程和用药结果 3个方面建立DUE标准细则。采用回顾性调查方法,对宁德市中医院2021年1—12月使用注射用纤溶酶的住院患者病历进行评价。结果 共纳入256份病历,用药合理率为61.72%。不合理用药情况主要包括用法用量不适宜(3.91%)、超说明书用药(1.95%)、未皮试(8.98%)、疗程不足或过长(25.00%)。结论 建立的注射用纤溶酶DUE标准细则有较强的科学性、实用性和可行性,在禁忌证、高凝血状态使用注射用纤溶酶、超说明书用药管理方面可进一步优化。

Objective To establish the drug use evaluation(DUE)standard of fibrinogenase for injection and provide a reference for the rational clinical application of fibrinogenase for injection.Methods Based on the specification of fibrinogenase for injection,the DUE standard was established from three aspects:drug indication,drug process and drug results,with reference to relevant guidelines and literature,and through discussion with clinical experts.A retrospective survey was conducted to evaluate the inpatients using fibrinogenase for injection from January 2021 to December 2021 in Ningde Hospital of Traditional Chinese Medicine,Fujian Province.Results A total of 256 patients were included,with a medication reasonable rate of 61.72%.The irrational use of drugs was mainly including the inappropriate usage and dosage(3.91%),off-label medication(1.95%),no skin test(8.98%),too long or inadequate course of medication(25.00%).Conclusion The DUE standard established of fibrinogenase for injection is scientific,practical and feasible.The use of fibrinogenase for injection in contraindications and high blood coagulation state,and off-label medication can be further optimized.